Form 4: HCA Healthcare Executive Acquires Stock Appreciation Rights

Michael S. Cuffe, EVP and Chief Clinical Officer at HCA Healthcare, acquired 11,171 stock appreciation rights on January 28, 2025.

Summary

• Michael S. Cuffe, an executive at HCA Healthcare, has reported the acquisition of 11,171 stock appreciation rights.
• These rights were granted on January 28, 2025, at a price of $328.7 per right.
• The stock appreciation rights vest in four equal annual installments starting on January 28, 2026.
• The rights expire on January 28, 2035.
• The underlying security for these rights is common stock, with each right representing one share.

Sentiment

Score: 7

Explanation: The document reflects a routine executive compensation event, which is generally positive as it aligns management with shareholder interests. There is no indication of any negative sentiment.

Positives

• The acquisition of stock appreciation rights by a key executive suggests confidence in the company's future performance.
• The vesting schedule of the rights incentivizes long-term commitment from the executive.

Risks

• The value of the stock appreciation rights is dependent on the future performance of HCA Healthcare's stock price.
• There is a risk that the stock price may not appreciate sufficiently to make the rights valuable.

Future Outlook

The stock appreciation rights vest over four years, indicating a long-term incentive for the executive.

Industry Context

This is a standard practice for executive compensation in publicly traded companies, aligning management's interests with those of shareholders.

Comparison to Industry Standards

• Stock appreciation rights are a common form of equity compensation for executives in the healthcare industry.
• Companies like Tenet Healthcare and Universal Health Services also use similar instruments to incentivize their leadership teams.
• The vesting schedule and terms of these rights are generally in line with industry norms.

Stakeholder Impact

• The acquisition of stock appreciation rights by an executive can be seen as a positive signal to shareholders, indicating management's confidence in the company's future performance.
• The vesting schedule of the rights incentivizes long-term commitment from the executive, which can benefit the company and its stakeholders.

Key Dates

Keywords

stock appreciation rights, HCA Healthcare, executive compensation, insider trading, equity, Michael S. Cuffe